You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca and Merck & Co announces that the Japanese Ministry of Health, Labour and Welfare has approved Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, Already a subscriber Login You have read all your free articles, to…
Moberg Pharma announced that their New Skin Spray SKU will be sold in 3 900 Walmart stores and in over 1 500 Walgreens stores. Opening orders expected to ship in mid-March. New Skin was aquired from Prestige Brands. In July 2016. New Skin is the #1 OTC liquid bandage brand…
Orion Corporation has signed a European wide marketing and distribution agreement with Marinus Pharmaceuticals for ganaxolone, a GABAA receptor modulator being investigated in multiple rare seizure disorders. Under the terms of the agreement, Orion will have the right to sell and market ganaxoAlready a subscriber Login You have read all your free articles,…
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a subpopulation of homologous recombinatAlready a subscriber Login You have read all your free articles, to continue reading subscribe to…
